Increased IDO1 expression in most solid cancers, coupled with the knowledge that decreased tryptophan and increased kynurenine resulting from IDO1 over-activity suppresses the immune response to cancer cells led to a concerted effort to discover and develop selective IDO1 inhibitors as anticancer drugs. Here, IDO1 is linked to cancer.